Deals
Actelion May Fetch $9.8 Billion as a Takeover Target
This article is for subscribers only.
Actelion Ltd., the Swiss drugmaker that may attract a takeover offer from Amgen Inc., could fetch as much as 9.7 billion Swiss francs ($9.8 billion) in an acquisition, according to analysts.
An acquirer may pay about 70 francs per share, according to the median of 7 analyst estimates compiled by Bloomberg. The range was 65 francs to 75 francs a share. The Allschwil, Switzerland-based company’s stock closed yesterday at 54.60 francs, giving Actelion a market value of about 7.06 billion francs.